Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Novonesis misses sales forecast as growth stalls in Agriculture, Energy & Tech unit

Published by Global Banking & Finance Review®

Posted on February 25, 2026

2 min read

Last updated: February 25, 2026

Spirax manufacturing facility showcasing growth in UK sales - Global Banking & Finance Review — Image of Spirax's manufacturing operations emphasizes the company's optimistic sales growth forecast for the second half of the year, reflecting strong performance in the finance sector.

Tags:foreign exchange

Quick Summary

Novonesis missed Q4 sales forecasts as Agriculture, Energy & Tech stalled, leaving EBITDA just under consensus. The company guided 2026 organic growth of 5–7% and a 37–38% margin amid currency headwinds.

Novonesis Misses Sales Target as Agriculture, Energy & Tech Growth Stalls

Q4 Performance and Segment Impact

Feb 25 (Reuters) - Danish biosolutions company Novonesis reported weaker-than-expected organic sales growth for the fourth quarter on Wednesday, held back by flat revenue in the Agriculture, Energy & Tech business.

Currency and Acquisition Effects

While the unit's euro sales were positively impacted by the 2025 acquisition of the remaining stake in Feed Enzyme Alliance, this development was offset by currency headwinds elsewhere, the group said in a statement, another European chemicals group grappling with strong home currencies eroding reported numbers.

Key Details

KEY DETAILS

* Novonesis delivered quarterly organic growth of 4%,against 5.2% seen in a company-provided consensus. * The biggest miss to analysts' expectations came within thePlanetary Health segment, where Agriculture, Energy & Tech sawno growth in euros versus 7% expected by analysts. * Quarterly adjusted earnings before interest, taxes,depreciation and amortization (EBITDA) were 364.6 million euros($429.9 million), 10 million euros below consensus. * For 2026, Novonesis guides for organic sales growthbetween 5-7% and a higher adjusted EBITDA margin of 37-38%,including currency headwinds of about 50 bps year-on-year. * Jyske Bank analysts said that late‑year signs of consumersoftness were hardly encouraging after a strong year. * Novonesis' shares have lost around 20% of their valuesince peaking in June 2025. They were broadly unchanged in earlyWednesday trading.

Exchange Rate Reference

($1 = 0.8480 euros)

Reporting and Editing Credits

(Reporting by Izabela Niemiec in Gdansk, editing by Milla Nissi-Prussak)

Key Takeaways

•Q4 organic sales growth landed below consensus, reflecting a softer finish to the year.
•Planetary Health underperformed as Agriculture, Energy & Tech posted flat growth versus expectations.
•Adjusted EBITDA came in slightly under analysts’ estimates, pressured by FX.
•For 2026, management guides 5–7% organic growth and a 37–38% adjusted EBITDA margin, assuming currency headwinds.
•The 2025 Feed Enzyme Alliance deal aided euro-reported sales but broader FX pressures offset the benefit.

Frequently Asked Questions about Novonesis misses sales forecast as growth stalls in Agriculture, Energy & Tech unit

1What is the main topic?

Novonesis’ fourth‑quarter results missed sales expectations as growth stalled in its Agriculture, Energy & Tech unit, prompting a cautious 2026 outlook for growth and margins.

2Why did Agriculture, Energy & Tech underperform?

The unit saw flat growth versus expectations. While euro‑reported sales were helped by the 2025 Feed Enzyme Alliance acquisition, currency headwinds and softness elsewhere offset the boost.

3What guidance did Novonesis provide for 2026?

Management targets 5–7% organic sales growth and a 37–38% adjusted EBITDA margin, factoring in continued currency headwinds and execution on pricing and synergy initiatives.

Q4 Performance and Segment Impact

Currency and Acquisition Effects

Key Details

KEY DETAILS

Exchange Rate Reference

($1 = 0.8480 euros)

Reporting and Editing Credits

(Reporting by Izabela Niemiec in Gdansk, editing by Milla Nissi-Prussak)

Key Takeaways

•Q4 organic sales growth landed below consensus, reflecting a softer finish to the year.

•Planetary Health underperformed as Agriculture, Energy & Tech posted flat growth versus expectations.

•Adjusted EBITDA came in slightly under analysts’ estimates, pressured by FX.

•For 2026, management guides 5–7% organic growth and a 37–38% adjusted EBITDA margin, assuming currency headwinds.

•The 2025 Feed Enzyme Alliance deal aided euro-reported sales but broader FX pressures offset the benefit.

Frequently Asked Questions

1What is the main topic?

Novonesis’ fourth‑quarter results missed sales expectations as growth stalled in its Agriculture, Energy & Tech unit, prompting a cautious 2026 outlook for growth and margins.

2Why did Agriculture, Energy & Tech underperform?

The unit saw flat growth versus expectations. While euro‑reported sales were helped by the 2025 Feed Enzyme Alliance acquisition, currency headwinds and softness elsewhere offset the boost.

3What guidance did Novonesis provide for 2026?

Management targets 5–7% organic sales growth and a 37–38% adjusted EBITDA margin, factoring in continued currency headwinds and execution on pricing and synergy initiatives.